找到相關結果： 80

《刺針 · 血液病學》：索樂匹尼布用于治療中國原發免疫性血小板減少症患者

Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study Xiaofan Liu, Hu Zhou, Yu Hu, Jie Yin, Junmin Li, Wenming Chen, Ruibin Huang

科學出版物 | 2023-03-17

JSMO2023: 呋喹替尼治療日本難治性轉移性結直腸癌患者

The outcome for patients in Japan from the FRESCO-2 multi-regional clinical trial of fruquintinib, an oral inhibitor of VEGFR-1, -2 and -3, are being presented at the 2023 Japanese Society of Medical Oncology Annual Meeting, taking place March 16-18

科學出版物 | 2022-09-12

ESMO2022: FRESCO-2研究: 一項旨在評估呋喹替尼用於治療難治性轉移性結直腸癌患者的療效和安全性的全球 III 期國際多中心臨床試驗

標題： FRESCO-2: A global Phase 3 multi-regional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer FRESCO-2研究: 一項旨在評估呋喹替尼用於治�

科學出版物 | 2022-06-06

ASCO2022: 索凡替尼在美國軟組織肉瘤患者中的應用

Surufatinib in U.S. patients with soft tissue sarcoma Authors Sujana Movva, Alexander I. Spira, Erika P. Hamilton, Judy S. Wang, Allen Lee Cohn, James F. Strauss, Silvia Stacchiotti, Chris Tucci, John Kauh, Shivani Nanda, Marek K. Kania, Sh

科學出版物 | 2022-06-06

ASCO2022: 兩項 Ⅲ 期臨床試驗中索凡替尼治療晚期 NETs 患者的安全性匯總分析

A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs Authors Jie Li, Jianming Xu, Lin Shen, Chunmei Bai, Zhiwei Zhou, Zhiping Li, Yihebali Chi, Xianjun Yu, Enxiao LI, Nong Xu, Tianshu Liu, Wenhui Lou, Yuxian Bai, Xia

科學出版物 | 2021-12-12

ASH 2021: 選擇性口服Syk抑制劑HMPL-523治療復發或難治性淋巴瘤患者的I期臨床試驗初步結果

1 個附件

查看海報 (PDF)

科學出版物 | 2021-11-03

NANETS 2021: 索凡替尼治療美國神經內分泌瘤患者的中期分析結果

1 個附件

查看海報 (PDF)

科學出版物 | 2021-09-17

ESMO 2021：呋喹替尼與替雷利珠單抗聯合療法治療晚期三陰性乳腺癌患者的Ib/II期研究

1 個附件

標題: An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple negative breast cancer 一項評估呋喹替尼與替雷利珠單抗聯合療法治

查看海報 (PDF)

演示文稿, 科學出版物 | 2021-06-22

《刺針 · 呼吸醫學》：賽沃替尼治療MET外顯子14 跳躍突變的中國非小細胞肺癌患者

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study Shun Lu, Jian Fang

科學出版物 | 2021-06-04

ASCO 2021: 多中心、開放標簽的I期研究︰評估HMPL-306治療伴有IDH突變的局部晚期或轉移性實體瘤患者的安全性和耐受性

1 個附件

標題: A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations. 一項多中心、開放標簽的I期研究︰評估HMPL-30

查看海報 (PDF)

科學出版物 | 2021-06-04

ASCO 2021: 索凡替尼聯合替雷利珠單抗治療晚期實體瘤患者的開放標簽的Ib/II期臨床研究

1 個附件

標題: An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors 索凡替尼聯合替雷利珠單抗治療晚期實體瘤患者的開放標簽的Ib/II期臨床研究主�

查看海報 (PDF)

科學出版物 | 2021-06-04

ASCO 2021: 索凡替尼治療美國神經內分泌瘤患者的中期分析結果

1 個附件

標題: Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs). 索凡替尼治療美國神經內分泌瘤患者的中期分析結果主要作者: Scott Paulson, MD, Baylor Sammons Cancer Center

查看海報 (PDF)

科學出版物 | 2021-04-09

AACR 2021: 賽沃替尼在伴有MET外顯子14跳變的NSCLC患者中的II期研究的ctDNA分析

1 個附件

AACR 2021: ctDNA Analysis in the Savolitinib Phase II Study in NSCLC Patients Harboring METex14 Skipping Alterations Presenter/Authors: Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang,

查看海報 (PDF)

演示文稿, 科學出版物 | 2021-03-04

ASCO-GI 2021: FRESCO-2 呋喹替尼國際III期結直腸癌研究

1 個附件

FRESCO-2: A global phase 3 study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC) Arvind Dasari, James Yao, Alberto Sobrero, Takayuki Yoshino, William Schelman, Shivani Nanda, Caly Chien, Su-Fen

查看海報 (PDF)

演示文稿, 科學出版物 | 2020-12-05

ASH2020: 選擇性口服PI3Kδ抑制劑HMPL-689治療中國復發/難治性淋巴瘤患者的I期劑量遞增研究結果

2 個附件

標題： Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with relapsed/refractory (R/R) Lymphoma 選擇性口服磷脂醯肌醇3-激酶亞型δ�

查看摘要 (PDF)下載演示文稿 (PDF)

演示文稿, 科學出版物 | 2020-09-21

《刺針·腫瘤學》：索凡替尼SANET-p III期研究

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Chunmei Bai*, Wei Wang*, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihe

演示文稿, 科學出版物 | 2020-09-21

《刺針·腫瘤學》：索凡替尼SANET-ep III期研究

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, T

演示文稿, 科學出版物 | 2020-09-20

ESMO2020: 索凡替尼治療晚期胰腺神經內分泌瘤患者（SANET-p）

1 個附件

標題：索凡替尼治療晚期胰腺神經內分泌瘤患者（SANET-p）：隨機、雙盲、安慰劑對照的III期臨床試驗 (NCT02589821) 主要作者：中國人民解放軍總醫院第五醫學中心消化腫瘤科主任 �

下載演示文稿 (PDF)

演示文稿, 科學出版物 | 2020-09-18

ESMO2020: 呋喹替尼治療晚期實體瘤患者的I/Ib期臨床試驗

1 個附件

標題：呋喹替尼治療晚期實體瘤患者的I/Ib期臨床試驗：難治性轉移性結直腸癌劑量遞增佇列的初步結果會議環節： N. Arvind Dasari, Associate Professor, Department of Gastrointestinal (GI) Medical

下載海報（PDF）

演示文稿, 科學出版物 | 2020-09-18

ESMO2020: 索凡替尼SANET-ep研究按Ki-67和原發腫瘤起源的亞組分析

1 個附件

標題：索凡替尼治療晚期高分化的非胰腺神經內分泌瘤的隨機、安慰劑對照的III期臨床試驗（SANET-ep）按Ki-67和原發腫瘤起源的亞組分析主要作者：中山大學腫瘤防治中心胃胰科�

下載海報（PDF）

演示文稿, 科學出版物 | 2020-04-27

AACR2020: 索凡替尼在中美患者中的藥代動力學特征及安全性比較

1 個附件

標題：索凡替尼在中美患者中的藥代動力學特征及安全性比較報告人： Arvind Dasari 作者： A Dasari1, S Paulson2, E Hamilton3, J Wang4, M Sung5, G Falchook6, C Tucci7, K Li7, C Chien7, J Kauh7, M Kani

下載演示文稿 (PDF)

演示文稿, 科學出版物 | 2020-04-27

AACR2020: 關於索凡替尼聯合特瑞普利單抗治療晚期實體瘤患者的I期臨床研究

1 個附件

標題：關於索凡替尼聯合特瑞普利單抗治療晚期實體瘤患者的I期臨床研究報告人：曹彥碩作者：陸明1, 曹彥碩1, 龔繼芳1, 孫宇2, 李潔1, 沈琳1. 1北京大學腫瘤醫院惡性腫

下載演示文稿 (PDF)

演示文稿, 科學出版物 | 2020-03-13

ENETS 2020 : 索凡替尼用於中國晚期非胰腺神經內分泌瘤患者的安全性和特殊不良事件：SANET-ep研究數據分析

1 個附件

>> 相關報道 The previously reported SANET-ep trial (clinicaltrials.gov identifier NCT02588170) demonstrated that surufatinib significantly improves progression-free survival (“PFS”) in patients with advanced extrapancreatic (non-panc

下載海報

演示文稿, 科學出版物 | 2020-02-06

《刺針·腫瘤學》奧希替尼與沃利替尼用于EGFR突變、MET擴增的非小細胞肺癌

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Lecia V Sequist;

演示文稿, 科學出版物 | 2019-09-29

ESMO 2019: 索凡替尼用於治療高分化的晚期非胰腺神經內分泌瘤患者的療效和安全性

標題：索凡替尼用於治療高分化的晚期非胰腺神經內分泌瘤患者的療效和安全性：隨機化的III期臨床試驗（SANET-ep）結果報告人：中國人民解放軍總醫院第五醫學中心消化腫瘤科

演示文稿, 科學出版物 | 2019-09-21

CSCO 2019: FRESCO研究中手足皮膚反應的發生情況及與療效的關係

報告 FRESCO 研究中手足皮膚反應的發生情況及與療效的關係報告人：白玉賢，哈爾濱醫科大學附屬腫瘤醫院其他作者：李進，秦叔逵，徐瑞華，沈琳，徐建明，鄧豔紅，楊�

演示文稿, 科學出版物 | 2019-09-19

CSCO 2019 : 呋喹替尼三線治療中國轉移性結直腸癌的III期臨床研究（FRESCO）中的肝轉移亞組分析

報告呋喹替尼三線治療中國轉移性結直腸癌的III 期臨床研究（FRESCO）中的肝轉移亞組分析報告人：秦叔逵，東部戰區總醫院（原八一醫院）其他作者：李進，徐瑞華，沈琳

演示文稿, 科學出版物 | 2019-09-09

WCLC 2019: 呋喹替尼治療晚期非小細胞肺癌（FALUCA）III期試驗

1 個附件

MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA) Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget

Download Presentation (PDF)

演示文稿, 科學出版物 | 2019-06-01

《Clinical Cancer Research》：索凡替尼在高分化神經內分泌瘤的使用

Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao

演示文稿, 科學出版物 | 2018-06-26

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;

演示文稿, 科學出版物 | 2018-06-04

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F

演示文稿, 科學出版物 | 2018-06-04

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO

Presenter: Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y

演示文稿, 科學出版物 | 2018-04-17

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib

4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets

演示文稿, 科學出版物 | 2018-03-23

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans

Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa

演示文稿, 科學出版物 | 2018-03-12

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC

Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung

演示文稿, 科學出版物 | 2018-02-24

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial

Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,

演示文稿, 科學出版物 | 2018-02-20

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can

演示文稿, 科學出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC

OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han

演示文稿, 科學出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC

OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T

演示文稿, 科學出版物 | 2017-10-15

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC

JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA

演示文稿, 科學出版物 | 2017-09-28

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer

Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,

演示文稿, 科學出版物 | 2017-09-28

CSCO 2017: Theliatinib Phase I Results

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif

演示文稿, 科學出版物 | 2017-09-27

CSCO 2017: FRESCO In-Depth Analysis

In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen

演示文稿, 科學出版物 | 2017-09-27

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer

Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi, Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei

演示文稿, 科學出版物 | 2017-06-23

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC

Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur

演示文稿, 科學出版物 | 2017-06-05

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)

A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol

演示文稿, 科學出版物 | 2017-06-05

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer

A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti

演示文稿, 科學出版物 | 2017-04-04

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases

Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,

演示文稿, 科學出版物 | 2017-04-03

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models

Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,

演示文稿, 科學出版物 | 2017-03-09

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors

An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase